Arch Dermatol
-
Clinical Trial
A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
To investigate the preliminary safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for atopic dermatitis. ⋯ These results support further development of apremilast for treatment of atopic dermatitis. Larger randomized controlled studies are needed to more adequately evaluate both safety and efficacy. Limitations include the small sample size and absence of a control.